Dr. Hill is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6565 Fannin St
Houston, TX 77030Phone+1 714-441-1450Fax+1 713-790-8750
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Vanderbilt University Medical CenterResidency, Internal Medicine, 2011 - 2014
University of Texas Medical Branch School of MedicineClass of 2011
Certifications & Licensure
TX State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells Start of enrollment: 2021 Aug 02
Publications & Presentations
PubMed
- 76 citationsNew and emerging therapies for acute and chronic graft versus host disease.LaQuisa Hill, Amin M. Alousi, Partow Kebriaei, Rohtesh S. Mehta, Katayoun Rezvani
Therapeutic Advances in Hematology. 2018-01-01 - 11 citationsAntitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas.LaQuisa C Hill, Rayne H Rouce, Mengfen J Wu, Tao Wang, Royce Ma
Blood. 2024-03-28 - 20 citationsHealth disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study.Samer Al Hadidi, Deepa Dongarwar, Hamisu M. Salihu, Rammurti T. Kamble, Premal Lulla
Leukemia & Lymphoma. 2021-07-18
Press Mentions
CAR T Cells Produce Complete Responses in T-cell MalignanciesJanuary 7th, 2020
Stand up to Cancer Dream Team Tackles T-cell Lymphoma, Focused on CAR-Based StrategiesJanuary 28th, 2019- CAR T Cell Therapy for T Cell Lymphoma Shows Promise in Phase I TrialJanuary 6th, 2024
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
